The US Surgical Matrices Market showed robust growth in Q419, improving on Q319. Breast matrices rebounded from its Q319 malaise, while hernia matrices grew YoY.

In Q419, the US Surgical Matrices Market grew +8.5% YoY, and was up +4.2% for FY19 according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan broke out of its  Alloderm supply constraints, and Becton Dickinson (BD) also did quite well.

• Q419 Breast Matrices market found its groove again, up YoY. For FY19 Breast Matrices grew well, despite several weak quarters.
• Q419 US Hernia Matrices market increased its growth, with the highest growth rate in biosynthetics and with both xenografts and allografts showing surprising strength. For the year, Hernia Matrices edged up.
• Allergan beat its supply constraints and maintained its leadership of the Breast Matrices market, as Alloderm returned to the market in force. For the full year, Allergan slid due to those Alloderm supply problems.
• BD maintained its No. 1 position in the Q419 Hernia Matrices market.

Among the many topics covered in the comprehensive Q419/FY19 US Surgical Matrices Market Recap* are:

Marcia Nusgart, Executive Director, Alliance of Wound Care Stakeholders, discusses the upcoming Wound Care Evidence Summit and improving payer coverage in an interview with SmartTRAK.

In the market for wound care products, the success of any product is highly dependent on whether or not manufacturers are able to obtain a positive coverage determination from public and commercial payers. In the last several years, obtaining product reimbursement has been more challenging as payers are restricting coverage for a growing number of wound care products due to a lack of clarity surrounding clinical evidence.

So, what are payers looking for? What and how much clinical evidence do payers need to cover wound care products and procedures? How can manufacturers prepare scientific evidence to meet payer needs, improve coverage and achieve more uniform policies for treating wounds in all healthcare settings? To answer these questions and more, the Alliance of Wound Care Stakeholders is convening payers, regulators, researchers, manufacturers and wound care providers at its upcoming Wound Care Evidence Summit to be held April 1-2, 2020 in Washington, DC.

To find out about the Summit, improving payer coverage and opportunities for industry, SmartTRAK’s Susan Paquette interviewed Marcia Nusgart, Executive Director of the Alliance of Wound Care Stakeholders.

A panel session at ACS Clinical Congress 2019 examines the evidence behind currently proposed techniques to prevent incisional hernias after midline laparotomy closure, including the use of prophylactic mesh and small-bite 4:1 suture closure.

At the American College of Surgeons (ACS) Clinical Congress 2019, there was an important session in which panelists discussed the advantages and disadvantages of using prophylactic mesh after closure of midline laparotomies to prevent incisional hernias. Ajita Prabhu, MD and Benjamin Poulose, MD moderated the panel session on October 28, 2019.

Heidi Miller, MD of University of New Mexico gave background on risk factors for incisional hernias, which she estimated at 12-13% incidence after closure of a laparotomy. She characterized incisional hernias as “mostly due to technical failures,” including poor wound hemostasis or coagulopathy, too much inflammation of the wound and the associated abnormal collagen structure, and sutures without proper tension. With respect to the latter topic, she described how she likes to view the hernia as a chronic wound, with proliferation and remodeling dependent on proper tension of approximation. She also described modifiable risk factors associated with the patient. Smoking and diabetes affect tissue perfusion, with strong data supporting tissue ischemia associated with smoking. Tissue perfusion greatly affects wound healing, as do modifiable factors that affect inflammation, including proper wound care, nutrition (especially vitamin A intake) and obesity, which is associated with chronic inflammation. Additionally, obesity is also associated with increased risk of wound dehiscence and increased mechanical stress tending to open the wound ...

SmartTRAK is pleased to welcome Anikó Szekér, the newest addition to our Wound Care team. Anikó has 10+ years of medical device experience in Wound Care and Surgical single use products. Before joining SmartTRAK, Anikó was  Marketing Manager, Eastern Europe Wound Care and Surgical at Mölnlycke Health Care.

Location: Northeast region of US (NY, NJ, MA, PA)

Full-time Position

Position:

BioMedGPS, a leading strategic advisory and healthcare analytics firm serving the life sciences industry, is seeking a Director of Enterprise Sales with extensive healthcare B2B experience for its SmartTRAK Business Intelligence platform and related products. Applicant must reside in the Northeastern region of the USA for easy access to major accounts.

SmartTRAK is the first business intelligence portal that provides real time data, analytics and curated content by a team of industry experts to help medical device executives make more informed strategic decisions. SmartTRAK is utilized by leading medical device companies within the orthopedic, wound care, regenerative medicine and neuro therapeutic areas. The Director of Sales will be responsible for selling SmartTRAK’s suite of business intelligence solutions to C- suite and other senior level executives, as well as building long term strategic programs and relationships at all levels of the enterprise.

The US market for Hemostats and Sealants grew +5.6% YoY in Q319, a continued deceleration from +6.4% YoY in Q219, with fibrin sealants and absorbable hemostats driving the increase.

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market experienced revenue growth in Q319. Leading the way was Becton Dickinson (BD), with Integra, Ethicon and Baxter all posting strong gains. The US Hemostats and Sealants market was up +5.6% YoY with all competitors posting gains for the quarter. Sealants continued their solid growth, up +6.5% YoY, with fibrin sealants leading the way. Absorbable hemostats resumed their leadership, contributing to the +5.1% YoY growth to...

Among the many topics covered in the complete, comprehensiveQ319 US Hemostats and Sealants Market Recap* are:

Positive gains in the mid-single digits for Q319, a slight decrease from previous quarter

Prevention of HAIs continues to drive measures and practices to reduce Central Line Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. In response, numerous programs and educational tools are being launched providing measures and strategies to assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Last quarter, a coalition of nurses and the AVA launched a drive to support a safety initiative for placing vascular access specialists in every hospital across America. This theme continued at this year’s AVA conference with the mission statement of “Protect the Patient, Educate the Clinician and Save the Line” highlighting the overall focus for the event. Acknowledgment of the importance of the vascular access nurse and team were featured in numerous studies and presentations demonstrating the value of the vascular access team in practice...

Among the many topics covered in the complete, comprehensive Q319 US Infection Prevention Market Recap* are:

Another quarter of strong growth, but slower growth clouds building up on the horizon here and there. Both Smith+Nephew and ConvaTec have newly appointed CEOs.

For Q319, according to SmartTRAK’s Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +5.9% YoY.

Acelity remained the WW AWC market leader, up +6.3% YoY, driven by  Prevena and the Crawford acquisition. WW Advanced Dressings saw several strong shifts in the ranking of companies, with ConvaTec moving up to the 2nd position, surpassing Smith + Nephew (S+N), after ConvaTec recovering, but S+N facing continued declining growth. Mölnlycke led the market and Coloplast was the strongest growing of the top four. The total market was up +3.2% YoY. US Skin/Dermal Substitute (CTP) revenue increased, with xenografts, especially  Organogenesis’  PuraPly, driving gains. WW NPWT was up  +8.2% YoY, with traditional devices up +3.4% and single-use...

Among the many topics covered in the complete, comprehensive Q319 Advanced Wound Care Market Recap* are: